AstraZeneca and Daiichi Sankyo pushed back the readout of their trial of Datroway in triple-negative breast cancer (TNBC) patients ineligible for frontline immunotherapies, but the result has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback